Dr Michael Mehler joins leon-nanodrugs as CEO

Munich-headquartered leon-nanodrugs has appointed Dr Michael Mehler as chief executive officer, succeeding Dr Ted Odlaug who moves to the supervisory board.

Dr Mehler brings over 25 years of leadership experience in the pharma and biotech industries, most recently as chief executive of SpePharm, a Switz specialty hospital products developer.

Prior to this, he was chief executive officer of Riemser Pharma, and held a number of positions at Actelion Pharmaceuticals, Merck & Co and Novartis.

Dr Hubert Birner, chairman of the leon-nanodrugs board, said: “We welcome Michael to lead leon nanodrugs on our joint journey to continued growth and internationalisation.

“We know Michael as a very experienced executive and look forward to working with him.

“We would also like to express our sincere appreciation to Ted who did a tremendously impressing job - he will obviously bring his valuable expertise to the board in his new role and continue to complement our management team.”